NRG GY004

Primary Category:

Treatment Protocols

Disease Category:

Gynecologic, Ovarian

Status:

Closed

A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum sensitive ovarian, fallopian tube, or primary peritoneal cancer

NCT#02446600

Closed to accrual effective November 10, 2017.  Accrual goal met.

This protocol has additional regulatory requirements to be completed prior to registering any patients at your site.  Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.